The Benefits of Combining Islet Cell Transplantation with Other Diabetes Treatments

Diabetes mellitus, particularly type 1 diabetes, remains a significant global health challenge affecting millions of people worldwide. Despite advances in insulin formulations and delivery technologies, achieving consistent normoglycemia and preventing long-term complications is often elusive for many patients. Islet cell transplantation has emerged as a cellular replacement therapy capable of restoring endogenous insulin secretion, yet it rarely achieves complete, lifelong independence from exogenous insulin when used alone. The strategic integration of islet transplantation with adjunctive pharmacological, immunological, and lifestyle interventions creates a synergistic framework that can enhance graft survival, improve metabolic control, and reduce the burden of disease. This article examines the rationale, evidence, and practical applications of combining islet cell transplantation with other diabetes treatments to optimize outcomes for patients with complicated diabetes.

Understanding Islet Cell Transplantation: The Foundation of Cellular Replacement

Islet cell transplantation involves the isolation of insulin-producing beta cells from a deceased donor pancreas and their infusion into the recipient’s portal vein, where they engraft in the liver and secrete insulin in response to glucose. The procedure was first successfully performed in the 1970s, but it was the Edmonton Protocol developed in 2000 that dramatically improved short-term insulin independence rates. However, long-term follow-up has shown that most recipients eventually require supplemental insulin again, highlighting the need for combinatorial strategies.

The procedure is typically reserved for patients with type 1 diabetes who experience hypoglycemia unawareness or severe glycemic lability—conditions that make standard insulin therapy inadequate. While a single infusion can restore near-normal glucose homeostasis for months or years, the transplanted islets face multiple threats: immediate immune-mediated attack, chronic rejection, metabolic stress from hyperglycemia, and the toxicity of immunosuppressive drugs themselves. These challenges underscore why combination therapy is not just beneficial but often necessary.

The typical transplant recipient undergoes one to three infusions over several months to achieve optimal islet mass. Each infusion contains roughly 400,000 to 600,000 islet equivalents. The engraftment process takes approximately two to three months, during which the islets revascularize and begin secreting insulin reliably. Even under ideal conditions, only about 30-40% of the infused islets survive long term, making any intervention that improves survival clinically valuable.

Rationale for Combining Treatments: Synergy Beyond Monotherapy

The core rationale for combining islet transplantation with other modalities rests on several interdependent goals: protecting the transplanted islets from destruction, maximizing their functional mass, and controlling the recipient’s systemic metabolic environment. No single intervention can address all these factors simultaneously. For instance, potent immunosuppression prevents rejection but can impair beta-cell regeneration and cause metabolic disturbances. Adjunctive medications and lifestyle modifications can offset these adverse effects while also improving the patient’s overall diabetes management.

By layering multiple approaches, clinicians can tailor therapy to individual patient profiles, reduce the required dose of each intervention, and mitigate side effects. This integrative approach aligns with modern precision medicine and has demonstrated tangible benefits in clinical trials and registry data. The concept mirrors successful strategies in oncology, where combination chemotherapy achieves outcomes unattainable with single agents.

Enhanced Graft Survival and Function

The survival of transplanted islets is influenced by both allo-immune and auto-immune responses, as well as the inflammatory milieu of the liver. Combining islet infusion with immunomodulatory agents that target specific pathways—such as T-cell costimulation blockers, tumor necrosis factor inhibitors, or regulatory T-cell induction—can significantly prolong graft function. Additionally, drugs that reduce beta-cell stress, such as glucagon-like peptide-1 receptor agonists, have been shown to improve islet engraftment and insulin secretion capacity. Studies indicate that the combination of etanercept (a TNF-α blocker) with standard immunosuppression increases the proportion of islets that engraft by more than 20%.

Improved Glycemic Control and Reduced Hypoglycemia

Even when complete insulin independence is not achieved, combined therapy can produce a hybrid state where the transplanted islets handle basal insulin needs and the patient uses minimal prandial insulin. This reduces the amplitude of blood glucose excursions and virtually eliminates severe hypoglycemic events—a primary endpoint in many clinical trials. Continuous glucose monitoring data from patients on combination protocols show higher time-in-range (often exceeding 80%) and lower glycemic variability compared to either transplantation alone or intensive insulin therapy. Patients consistently report dramatic improvements in quality of life, including the ability to sleep without fear of nocturnal hypoglycemia.

Stable normoglycemia is the most powerful intervention to slow or prevent microvascular complications. Combined strategies that achieve sustained glucose control can reduce the progression of diabetic retinopathy, neuropathy, and nephropathy. Furthermore, the lower insulin requirements associated with successful islet function may lessen the metabolic burden of high-dose exogenous insulin, which can contribute to weight gain and cardiovascular risk. Registry data show that patients who achieve sustained graft function have a 50% lower incidence of new microalbuminuria compared to those who lose graft function within the first year.

Key Treatment Combinations and Their Evidence Base

Immunosuppressant Regimens Tailored for Islet Survival

The backbone of islet transplantation is immunosuppression, but the optimal regimen continues to evolve. The Edmonton Protocol used a steroid-free combination of sirolimus, tacrolimus, and daclizumab. While effective initially, long-term nephrotoxicity and metabolic side effects limited durability. Modern approaches often replace sirolimus with mycophenolate mofetil and use induction therapy with alemtuzumab or anti-thymocyte globulin. More recently, belatacept (a selective T-cell costimulation blocker) has shown promise in reducing renal toxicity while maintaining adequate immunosuppression. Clinical studies have demonstrated that belatacept-based regimens result in higher rates of insulin independence at 5 years compared to calcineurin inhibitor-based protocols. A multicenter trial reported that 72% of patients on belatacept maintained insulin independence at three years versus 44% on tacrolimus.

Adjunctive Glucose-Lowering Medications

Several classes of non-insulin antihyperglycemic agents have been repurposed to support islet function:

  • GLP-1 receptor agonists: Exenatide and liraglutide augment glucose-dependent insulin secretion and promote beta-cell proliferation in vitro. A pilot study in islet transplant recipients showed that adding exenatide improved graft function and allowed lowering of the immunosuppressant dose. Long-term follow-up of these patients revealed sustained C-peptide production beyond five years.
  • DPP-4 inhibitors: Sitagliptin prevents degradation of endogenous GLP-1. Early evidence suggests it may enhance insulin secretion from transplanted islets without causing hypoglycemia. A randomized controlled trial demonstrated that sitagliptin added to standard immunosuppression increased insulin independence rates from 38% to 52% at one year.
  • SGLT2 inhibitors: Although not yet standard in transplant, these agents reduce hyperglycemia independently of insulin. They may protect islets from glucotoxicity and exert anti-inflammatory effects. Ongoing trials are evaluating their safety in immunosuppressed patients. Preclinical data show that dapagliflozin improves islet graft survival by reducing oxidative stress in the liver microenvironment.

Insulin Delivery Technology and Glucose Monitoring

Islet transplantation does not eliminate the need for insulin in many patients, but the quantity required typically drops by more than 90%. Integrating automated insulin delivery systems (hybrid closed-loop pumps) with a functioning islet graft creates a safety net: the pump manages residual needs, while the islets provide natural counter-regulation. Continuous glucose monitors paired with predictive alerts can further reduce the risk of hypoglycemia. This combination is particularly valuable in the early post-transplant period when grafts are still maturing and insulin requirements fluctuate. Patients using hybrid closed-loop systems after islet transplant achieve a time-in-range of over 90%, compared to 75% with standard pump therapy.

Lifestyle Interventions and Nutrition

Dietary modification, regular physical activity, and stress management directly impact the metabolic environment in which transplanted islets function. High-carbohydrate meals cause postprandial hyperglycemia that stresses beta cells, while a Mediterranean diet rich in unsaturated fats and fiber has been associated with better graft outcomes in observational studies. Exercise improves insulin sensitivity, lowers systemic inflammation, and may promote islet revascularization. Patients who adhere to structured lifestyle programs after transplantation show superior glycemic control and fewer hospitalizations for diabetic ketoacidosis. A prospective study found that participants who engaged in at least 150 minutes of moderate exercise per week had a 40% lower risk of graft failure at two years compared to sedentary recipients.

Immunomodulatory Strategies Beyond Conventional Drugs

Regulatory T-Cell Therapy

One of the most exciting frontiers in combination therapy is the use of ex vivo expanded regulatory T-cells (Tregs) to induce donor-specific tolerance. Infusion of autologous Tregs alongside the islet graft can suppress allo- and auto-reactive effector T-cells without broad immunosuppression. Phase I/II trials such as the ONE Study have demonstrated safety and reduced requirement for calcineurin inhibitors. Patients receiving Treg therapy combined with low-dose sirolimus have maintained graft function for years with fewer infectious complications. Current research focuses on optimizing the Treg-to-effector cell ratio and developing antigen-specific Tregs that target only the donor islets.

Anti-Inflammatory Agents and the Instant Blood-Mediated Inflammatory Reaction

The instant blood-mediated inflammatory reaction (IBMIR) occurring when islets enter the portal vein destroys a significant fraction of the infused cells. Co-administration of heparin, complement inhibitors, or TNF-α blockers (e.g., etanercept) during transplantation can mitigate this loss. Clinical series using anti-inflammatory prophylaxis have achieved insulin independence at 1 year in over 70% of recipients—a major improvement over historical controls where rates were below 40%. Newer approaches include the use of C1 esterase inhibitors and soluble complement receptor type 1 to block IBMIR more effectively.

Encapsulation and Immune Protection

Another combinatorial approach involves enclosing islets in biocompatible capsules that allow glucose and insulin diffusion while blocking immune cells. Macroencapsulation devices (e.g., ViaCyte’s PEC-Direct) are being tested in combination with donor stem cells and targeted immunosuppression. Even without full immune isolation, these devices reduce the amount of systemic immunosuppression needed. Current trials show that encapsulated islet cells can maintain C-peptide production for more than 12 months, and when combined with a single immunosuppressant, they achieve glycemic benefits without calcineurin inhibitor toxicity. Microencapsulation using alginate coatings that incorporate immunomodulatory cytokines or chemokine inhibitors is also under investigation.

Clinical Outcomes and Real-World Evidence

The Collaborative Islet Transplant Registry (CITR) tracks outcomes from centers worldwide. According to CITR data from over 1,000 recipients, the rate of insulin independence at 3 years increased from 30% in the early era to over 60% in patients receiving modern combined protocols. More importantly, freedom from severe hypoglycemia—a key quality-of-life endpoint—was achieved in over 90% of patients regardless of insulin use. These figures demonstrate that combination therapy is not academic theory but translates into tangible survival and functional benefits.

A landmark study from the University of Chicago reported that patients receiving islet transplantation plus GLP-1 agonist therapy had significantly higher time-in-range (85% versus 65%) and lower glycated hemoglobin (6.1% versus 7.2%) than those receiving transplantation alone. Similar results have been replicated in European centers using triple therapy: islets, sitagliptin, and tight lifestyle management. A recent analysis of the CITR database showed that patients who received a combination of at least two adjunctive therapies had a 50% lower rate of graft loss at five years compared to those receiving transplantation with only baseline immunosuppression.

Challenges and Limitations of Combination Therapy

Despite the promise, combining multiple treatments introduces complexity. Immunosuppressive drugs carry risks of infection, malignancy, and organ toxicity. Adding antiproliferative agents or angiotensin-converting enzyme inhibitors for nephroprotection increases pill burden and requires careful monitoring. The cost of triple therapy plus transplantation is substantial, and insurance coverage varies by region. Moreover, the shortage of donor pancreata limits widespread application; fewer than 2,000 islet transplants are performed annually worldwide.

Another limitation is the need for chronic immunosuppression in recipients who are not receiving a simultaneous kidney transplant. The risk-benefit calculus favors patients with severe hypoglycemia unawareness, but for those with reasonable metabolic control, the downsides may outweigh the gains. Therefore, combination therapy must be personalized based on each patient’s glycemic profile, cardiovascular health, renal function, and psychosocial readiness. Nonadherence to the complex medication and monitoring regimens remains a significant issue, with rates of late graft loss from nonadherence approaching 15% in some cohorts.

Additionally, the interaction between multiple drugs can lead to unexpected side effects. For example, combining GLP-1 agonists with calcineurin inhibitors can cause gastrointestinal intolerance, while SGLT2 inhibitors increase the risk of urinary tract infections in immunosuppressed patients. Close monitoring by a multidisciplinary team is essential to manage these risks.

Future Directions: Toward Immunosuppression-Free Transplantation

Research is actively pursuing ways to reduce or eliminate the need for lifelong immunosuppression. Stem cell-derived beta cells (e.g., from induced pluripotent stem cells) are being combined with immune-protective devices and targeted immunomodulation to create “off-the-shelf” products. Gene editing using CRISPR-Cas9 can render stem cells hypoimmunogenic by knocking out human leukocyte antigen genes or inserting immunomodulatory molecules. Preclinical models show that these engineered islet grafts survive without immunosuppression in non-human primates.

Xenotransplantation from genetically modified pigs (lacking alpha-gal and expressing human complement regulators) combined with co-stimulation blockade is another promising avenue. If these technologies reach clinical practice, the combinatorial paradigm will shift from managing donor scarcity to optimizing graft longevity and minimizing medication side effects. Clinical trials of porcine islet xenotransplantation in New Zealand have already shown safety and efficacy for up to five years in a small number of patients.

Finally, digital health tools—such as machine learning algorithms that predict glycemic patterns—may soon be integrated post-transplant to automatically adjust insulin delivery and medication dosing. The convergence of cellular therapy, pharmacology, and artificial intelligence represents the ultimate evolution of combination treatment. Early proof-of-concept studies using smartphone apps to track dietary intake and activity have demonstrated improved glycemic outcomes in islet transplant recipients.

Patient Selection and Multidisciplinary Care

Successful combination therapy requires careful patient selection and a multidisciplinary team including transplant surgeons, endocrinologists, dietitians, psychologists, and diabetes educators. Candidates are typically those with type 1 diabetes who have persistent glycemic instability despite optimized medical therapy, especially those with hypoglycemia unawareness. Absolute contraindications include active malignancy, untreated infections, and severe psychiatric disorders. Relative contraindications such as obesity, smoking, or renal impairment must be addressed before transplantation.

The evaluation process often includes comprehensive metabolic profiling, continuous glucose monitoring for two weeks, and assessment of psychosocial readiness. Patients need to understand that combination therapy may not eliminate the need for insulin entirely but will likely reduce hypoglycemia risk and improve quality of life. Informed consent involves discussion of potential side effects, the need for lifelong follow-up, and the possibility of needing additional infusions.

Conclusion

Islet cell transplantation alone is a powerful but incomplete therapy for type 1 diabetes. When combined with modern immunosuppressive regimens, glucose-lowering adjuncts, continuous glucose monitoring, lifestyle changes, and emerging immunomodulatory therapies, it can achieve levels of glycemic control and quality of life that are unattainable by any single modality. The evidence is clear: integrated combination therapy reduces insulin dependence, eliminates severe hypoglycemia, and protects against long-term complications. As research continues to refine these strategies and address current limitations, a growing number of patients will benefit from this multimodal approach. The future of diabetes management lies not in isolated interventions but in the thoughtful orchestration of multiple treatments working in concert.

For further reading, see the NIDDK Islet Transplantation page, the Collaborative Islet Transplant Registry, recent reviews in PubMed on combination strategies, and clinical trial information at ClinicalTrials.gov.